Invivogen
Menu

Anti-hCD20-hIgG4 (S228P)

Anti-hCD20-hIgG4 (S228P) Unit size Cat. code Docs Qty Price
Engineered monoclonal human IgG4 antibody against human CD20
100 µg
hcd20-mab14
+-
$331.00

Engineered monoclonal human IgG4 antibody against human CD20

Anti-hCD20-hIgG4 (S228P) features the variable region of rituximab and a mutated constant region of the human IgG4 isotype reported to reduce Fab-arm exchange [1].

Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

Anti-hCD20-hIgG4 (S228P) is an engineered human IgG4 isotype. IgG4 antibodies display low antibody-dependent cell-mediated cytotoxicity (ADCC) and no complement-dependent cytotoxicity (CDC). IgG4s are dynamic molecules that exchange Fab arms by swapping a heavy chain and attached light chain (half molecule) with a heavy-light chain pair from another molecule, resulting in bispecific antibodies [1, 2]. IgG4 molecules thereby lose their ability to cross-link antigen and to form immune complexes under most conditions [2]. Thus, mutations that prevent Fab-arm exchange in vivo should be considered when designing therapeutic IgG4.

The constant region of Anti-hCD20-hIgG4 (S228P) contains the S228P mutation which reduces Fab-arm exchange by stabilizing the disulfides in the core-hinge of the IgG4 molecules [1].
Anti-hCD20-hIgG4 (S228P) was generated by recombinant DNA technology.
It has been produced in CHO cells and purified by affinity chromatography with protein G.

1. Labrijn AF. et al., 2009. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 27(8):767-71.
2. van der Neut Kolfschoten M. et al., 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 317(5844):1554-7.

Back to the top

Specifications

Clonality: Engineered monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgG4
Application :
Anti-hCD20-hIgG4 (S228P) can be compared with anti-hCD20-hIgG4 to study the impact of Fab-arm exchange.

Quality control
- The absence of bacterial contamination (e.g. endotoxins and peptidoglycans) is controlled using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
- The recognition of human CD20 with this antibody is tested using flow cytometry.

Back to the top

Contents

100 µg purified anti-hCD20-hIgG4 (S228P) antibody, provided azide-free and lyophilized.

Store lyophilized antibody at -20°C. Lyophilized product is stable for 1 year.

Back to the top

Customer Service
& Technical Support

CAPTCHA
In order to prevent automated spam submissions, please answer the following question:
8 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Shopping cart is empty